Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel
Identificadores
Identificadores
URI: http://hdl.handle.net/20.500.11940/10801
PMID: 27239176
DOI: 10.1159/000443601
ISSN: 1661-3791
ESSN: 1661-3805
Visualización o descarga de ficheros
Visualización o descarga de ficheros
Fecha de publicación
2016Título de revista
Breast Care
Tipo de contenido
Artigo
DeCS
neoplasias de la mama | receptor del factor de crecimiento epidérmico | oncología médica | mama | factor de crecimiento epidérmicoMeSH
Breast | Breast Neoplasms | Epidermal Growth Factor | Medical Oncology | Receptor, Epidermal Growth FactorCIE
Tumor maligno de la mamaResumen
BACKGROUND:
The aim of this project was to provide an expert opinion regarding anti-human epidermal growth factor receptor 2 (HER2) therapy beyond second-line treatment of metastatic breast cancer (mBC).
METHODS:
A group of experts discussed specific issues concerning anti-HER2 therapy in late-line settings in mBC.
RESULTS:
Trastuzumab emtansine (T-DM1) or dual HER2 blockade appeared to be good options for HER2-positive mBC after ≥ 2 HER2-targeted therapies. Once an objective response has been achieved with anti-HER2-containing therapy, the anti-HER2 agent can be continued until progression of the disease, unacceptable toxicity or patient decision. mBC treated with ≥ 3 consecutive lines of anti-HER therapy, ≥ 1 being a dual HER2 blockade and with early progression of disease during a fourth or later-line treatment, are clinically resistant to anti-HER therapy. For progression of metastasis in the brain after anti-HER2 therapy, lapatinib and chemotherapy appear to be a good alternative after best local treatment.
CONCLUSIONS:
Further clinical trials are needed to provide valuable knowledge about the best treatment options in the later settings of mBC.